Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

September 30, 2005

Study Completion Date

April 30, 2009

Conditions
Lung Cancer
Interventions
DRUG

Celecoxib

On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals

DRUG

Docetaxel

On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00030407 - Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter